Citadel Advisors
STRO icon

Citadel Advisors’s Sutro Biopharma STRO Stock Holding History

Citadel Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$618K Buy
+24,800
New +$448K ﹤0.01% 8780
2025
Q2 		– Sell
-3,850
Closed -$25K – 14984
2025
Q1 		$25K Buy
3,850
+2,190
+132% +$34.5K ﹤0.01% 12973
2024
Q4 		$30.5K Buy
1,660
+550
+50% +$16.8K ﹤0.01% 12864
2024
Q3 		$38.4K Buy
1,110
+740
+200% +$29K ﹤0.01% 12179
2024
Q2 		$10.8K Buy
370
+130
+54% +$5.14K ﹤0.01% 13067
2024
Q1 		$13.6K Buy
240
+130
+118% +$5.74K ﹤0.01% 13292
2023
Q4 		$4.72K Hold
110
– – ﹤0.01% 13488
2023
Q3 		$3.82K Hold
110
– – ﹤0.01% 13544
2023
Q2 		$5.12K Hold
110
– – ﹤0.01% 13532
2023
Q1 		$5.08K Hold
110
– – ﹤0.01% 13894
2022
Q4 		$8.89K Buy
+110
New +$7.64K ﹤0.01% 13721
2022
Q3 		– Sell
-3,230
Closed -$168K – 13570
2022
Q2 		$168K Buy
+3,230
New +$180K ﹤0.01% 10867
2021
Q2 		– Sell
-1,750
Closed -$398K – 14401
2021
Q1 		$398K Buy
+1,750
New +$415K ﹤0.01% 10187

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors's STRO Position: Q1 2026 in Review

Citadel Advisors increased its Sutro Biopharma (STRO) stake by 266% in Q1 2026, buying an estimated $1.54M and bringing the position to 117,537 shares worth $2.93M. The position accounts for ﹤0.01% of the portfolio, ranked #5313.

Citadel Advisors first reported a position in STRO in Q3 2018 and has held it in 29 quarters since. The position peaked at $28.1M in Q4 2020. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Citadel Advisors held 117,537 shares of Sutro Biopharma worth $2.93M as of Q1 2026.
  • Citadel Advisors bought 85,452 Sutro Biopharma shares in Q1 2026, an estimated $1.54M.
  • Sutro Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5313 holding.
  • Citadel Advisors first reported a position in Sutro Biopharma in Q3 2018 and has held it in 29 quarters since.
  • Citadel Advisors's Sutro Biopharma position peaked at $28.1M in Q4 2020.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.